IP Library › Granted Patent US 12,264,147
Granted Patent B2
US 12,264,147 · App. 17/738,707 · Granted Apr 1, 2025

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

Inventors: Rima Al-Awar (Toronto, CA); Carlos Armando Zepeda-Velazquez (Mississauga, CA); Gennady Poda (Toronto, CA); Methvin Isaac (Brampton, CA); David Uehling (Toronto, CA); Brian Wilson (Mississauga, CA); Babu Joseph (Oakville, CA); Yong Liu (Oakville, CA); Pandiaraju Subramanian (Oakville, CA); Ahmed Mamai (Mississauga, CA); Michael Prakesch (Toronto, CA); Julia Katheleen Stille (Ottawa, CA)
Assignee: Propellon Therapeutics Inc.
C07D401/12A61K45/06C07D401/10C07D401/14C07D403/10C07D405/14C07D413/14C07D417/12C07D417/14A61P35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,147
App. No.
17/738,707
Granted
Apr 1, 2025
Kind
B2
Abstract

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Claims (4)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2026
From: AL-AWAR, RIMA; ZEPEDA-VELAZQUEZ, CARLOS ARMANDO; PODA, GENNADY; ISAAC, METHVIN; UEHLING, DAVID; WILSON, BRIAN; JOSEPH, BABU; LIU, YONG; SUBRAMANIAN, PANDIARAJU; MAMAI, AHMED; PRAKESCH, MICHAEL; STILLE, JULIA KATHLEEN
To: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
Reel/Frame 075388/0989 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2026
From: FIGHT AGAINST CANCER INNOVATION TRUST
To: PROPELLON THERAPEUTICS INC.
Reel/Frame 075389/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2025
From: PROPELLON THERAPEUTICS INC.
To: FACIT INC.
Reel/Frame 071708/0419 →
Continuity (4)
Continuation 17484534 · Sep 24, 2021
Continuation 16080866
Provisional Application 62301673 · Mar 1, 2016
Related Publication 20230219926A1 · Jul 13, 2023
References Cited (81)
US 5981537A · Nugent et al. · 1999 [cited by applicant]
US 6288055B1 · Natarajan et al. · 2001 [cited by applicant]
US 7169791B2 · Breitenstein et al. · 2007 [cited by applicant]
US 7230001B1 · Rudolf et al. · 2007 [cited by applicant]
US 7312341B2 · Desimone et al. · 2007 [cited by applicant]
US 7547804B2 · Bajji et al. · 2009 [cited by applicant]
US 7745437B2 · Ren et al. · 2010 [cited by applicant]
US 7807679B2 · Cassayre et al. · 2010 [cited by applicant]
US 7947696B2 · Eggenweiler et al. · 2011 [cited by applicant]
US 8193239B2 · Ford et al. · 2012 [cited by applicant]
US 8748423B2 · Hangauer et al. · 2014 [cited by applicant]
US 9079866B2 · Bacani et al. · 2015 [cited by applicant]
US 10160763B2 · Fesik et al. · 2018 [cited by applicant]
US 10501466B2 · Fesik et al. · 2019 [cited by applicant]
US 20010051719A1 · Bromidge et al. · 2001 [cited by applicant]
US 20070254894A1 · Kane et al. · 2007 [cited by applicant]
US 20090069327A1 · Ding et al. · 2009 [cited by applicant]
US 20090105250A1 · Sim et al. · 2009 [cited by applicant]
US 20090233905A1 · Burke et al. · 2009 [cited by applicant]
US 20100184765A1 · Huang et al. · 2010 [cited by applicant]
US 20120208815A1 · Burger et al. · 2012 [cited by applicant]
US 20150266881A1 · Tomita et al. · 2015 [cited by applicant]
US 20160311807A1 · Treon et al. · 2016 [cited by applicant]
US 20160318878A1 · Treon et al. · 2016 [cited by applicant]
US 20190112290A1 · Al-awar et al. · 2019 [cited by applicant]
US 20190119264A1 · Al-awar et al. · 2019 [cited by applicant]
US 20200385371A1 · Al-awar et al. · 2020 [cited by applicant]
CA 2944959A1 · 2015 [cited by applicant]
CN 100355751C · 2007 [cited by applicant]
CN 101875617A · 2010 [cited by applicant]
CN 105175284A · 2015 [cited by applicant]
CN 105585565A · 2016 [cited by applicant]
JP H0959236A · 1997 [cited by applicant]
JP 2010520228A · 2010 [cited by applicant]
WO 0172745A1 · 2001 [cited by applicant]
WO 0244153A1 · 2002 [cited by applicant]
WO 02088101A2 · 2002 [cited by applicant]
WO 2006124731A2 · 2006 [cited by applicant]
WO 2008106692A1 · 2008 [cited by applicant]
WO 2011149874A2 · 2011 [cited by applicant]
WO 2011156557A2 · 2011 [cited by applicant]
WO 2011159685A2 · 2011 [cited by applicant]
WO 2012066065A1 · 2012 [cited by applicant]
WO 2014003124A1 · 2014 [cited by applicant]
WO 2014048878A1 · 2014 [cited by applicant]
WO 2014121055A2 · 2014 [cited by applicant]
WO 2016112846A1 · 2016 [cited by applicant]
WO 2017147701A1 · 2017 [cited by applicant]
WO WO2017147700A1 · 2017 [cited by examiner]
WO 2017221092A1 · 2017 [cited by applicant]
WO 2020086857A1 · 2020 [cited by applicant]
WO 2021028806A1 · 2021 [cited by applicant]
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. [cited by examiner]
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface. [cited by examiner]
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18. [cited by examiner]
Bolshan et al. (2013) “Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction”, ACS Medicinal Chemistry Letters, 4(3):353-357. [cited by applicant]
Carugo et al. Jun. 2016 “In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5- Myc Association as a Critical Determinant of Pancreatic Cancer”, Cell Reports, 16(1):133-147. [cited by applicant]
Cheung et al. (Aug. 2011) “Methylation of an Intronic Region Regulates miR-199a in Testicular Tumor Malignancy”, Oncogene., 30(31):3404-3415. [cited by applicant]
Costa et al. (Jan. 2010) “Reversing HOXA9 Oncogene Activation by PBK Inlribition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma”, Cancer Research, 70(2):453-462. [cited by applicant]
Dubuc et al. (Mar. 2013) “Aberrant Patterns of H3K4 and H3K27 Histone Lysine Methylation Occur Across Subgroups in Medulloblastoma”, Acta Neuropathologica, 125(3):373-384. [cited by applicant]
Gallo et al. (Jan. 2013) “A Tumorigenic MLL-homeobox Network in Human Glioblastoma Stem Cells”, Cancer Research, 73(1):417-427. [cited by applicant]
Getlik et al. (2016) “Structure-Based Optimization of a Small Molecule Antagonist of the Interaction between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLLJ)”, Journal of Medicinal Chemistry, 59… [cited by applicant]
Grebien et al. (2015) “Pharmacological Targeting of the Wdr5-MLL Interaction in C/EBPa N-terminal Leukemia”, Nature Chemical Biology, 11(8):571-578(11 pages). [cited by applicant]
Hackam et al. (2006) “Translation of Research Evidence From Animals to Humans”, JAMA, 296(14):1731-1732. [cited by applicant]
Irizarry et al. (Feb. 2009) “The Human Colon Cancer Methylome Shows Similar Hypo- and Hypermethylation at Conserved Tissue-Specific CpG Island Shores”, Nature Genetics, 41(2):178-186. [cited by applicant]
Karatas et al. (2010) “Analysis of the Binding Mixed Lineage Leukemia 1 (MLLI) and Histone 3 Peptides to WD repeat Domain 5 (WDR%) for the design of Inhibitors of the MLL1-WDR5 Interaction”, Journal of Medicinal Chemist… [cited by applicant]
Karatas et al. (2015) “Structure-based Design Of Conformationally Constrained Cyclic Peptidomimetics To Targetthe MLL1-WDR5 Protein-protein Interaction As Inhibitors Of The MLL1 Methyltransferase Activity”, Chinese Chem… [cited by applicant]
Kim et al. (May 2014) “A Role for WDR5 in Integrating Threonine 11 Phosphorylation to Lysine 4 Methylation on Histone H3 During Androgen Signaling and in Prostate Cancer”, Molecular Cell, 54(4):613-625. [cited by applicant]
Li et al. (Aug. 2015) “Pygo2 siRNA Inhibit the Growth and Increase Apoptosis of U251 Cell by Suppressing Histone H3K4 Trimethylation”, Journal of Molecular Neuroscience, 56(4):949-955. [cited by applicant]
Li et al. (2016) “Structure-based Design and Synthesis of Small Molecular Inhibitors Disturbing the Interaction of MLL1-WDR5”, European Journal of Medicinal Chemistry, 118:1-8. [cited by applicant]
Molyneux et al. (Mar. 2012) “Burkitt's lymphoma”, Lancet, 379(9822):1234-1244. [cited by applicant]
Sausen et al. (2015) “Clinical Implications of Genomic Alterations in the Tumour and Circulation of Pancreatic Cancer Patients”, Nature Communications, 6:7686(15 pages). [cited by applicant]
Schneider et al. (2016) “In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis”, Trends in Cancer, 2(8):391-392. [cited by applicant]
Senisterra et al. (2013) “Small-molecule Inhibition of MLL Activity by Disruption of its Interaction with WDR5”, Biochemical Journal, 449(1):151-159(13 pages). [cited by applicant]
Song et al. (2008) “WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-binding Pocket”, Journal of Biological Chemistry, 283(50):35258-35264. [cited by applicant]
Sun et al. (Jul. 2016) “LncRNA GCIncl Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern”, Cancer Discovery, 6(7):784-801. [cited by applicant]
Thomas et al. (May 2015) “Interaction With WDR5 Promotes Target Gene Recognition And Tumorigenesis By MYC”, Molecular Cell, 58(3):440-452. [cited by applicant]
Wermuth, Camilleg. (1996) “Molecular Variations Based on Isosteric Replacements”, Practice of Medicinal Chemistry, 203-237. [cited by applicant]
Zhao et al. (Dec. 2015) “Expression and Clinical Role of RBQ3 in Gliomas”, The Journal of Neurological Science, 359(1-2):177-184. [cited by applicant]
Zhao et al. (Nov. 2014) “Methylation Of DACT2 Promotes Papillary Thyroid Cancer Metastasis By Activating Wnt Signaling”, PLoS One, 9(11):e112336. [cited by applicant]
Zhou et al. (Feb. 2016) “Pygo2 Functions As A Prognostic Factor For Glioma Due To Its Up-regulation Of H3K4ME3 And Promotion of mLL1/MLL2 Complex Recruitment”, Scientific Reports, 6:22066. [cited by applicant]